FundedIQ
Biotechnology

Precirix: Funding, Investors & Team (Sep 2026)

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

www.precirix.com LinkedIn Brussels, Belgium 11-50 employees
Total raised
$88.2M
Rounds
1
Latest
Series B
Mar 2022

Precirix has raised $88.2M across 1 funding round on record, the most recent a Series B of $88.2M announced in Mar 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Precirix Company Profile and Key Stats

Total funding raised
$88.2M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$88.2M in Mar 2022
Employees
11-50
reported band
Headquarters
Brussels, Belgium

Latest funding round on record: Mar 2022.

Precirix Funding Rounds

Date
Round
Amount
Series B
$88.2M

Precirix Founders and Leadership Team

Name
Role
Contact
Geert Raes
Founder
Locked

Contact details for the Precirix team: 1 of 1 has an email address on file.

Start 14-day free trial →

Precirix Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
298
$2.3M
4,289
$30M

Precirix's latest round of $88.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Precirix in Biotechnology and Brussels

Companies Similar to Precirix

MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…

Seed $6.8M

Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.

Undisclosed round $2.2M

Nyxoah is a health-technology company focused on the development and commercialization of innovative…

Undisclosed round $15.0M

Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…

Series A $125M

neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…

Series A $11.5M

Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…

Undisclosed round $6.1M

Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…

Undisclosed round $1.2M

Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…

Series B $11.8M

Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…

Series A $84.1M

4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…

Seed $1.0M

Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…

Undisclosed round $360k

AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…

Series D $88.8M

Precirix Funding FAQs

What does Precirix do?

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

How much funding has Precirix raised?

Precirix has raised $88.2M across 1 round on record. The most recent is a Series B of $88.2M announced in Mar 2022.

When did Precirix last raise funding?

Precirix's most recent funding round on record is a Series B of $88.2M, announced in Mar 2022.

Who founded Precirix?

FundedIQ lists Geert Raes (Founder) at Precirix.

Where is Precirix headquartered?

Precirix is based in Brussels, Brussels Hoofdstedelijk Gewest, Belgium.

How many employees does Precirix have?

Precirix is in the 11-50 employee band.

How does Precirix's funding compare to other Biotechnology startups?

Precirix's latest round of $88.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Precirix Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Precirix is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.